ELISA Kit Used to Measure Predictive Marker for Diabetic Kidney Disease
By LabMedica International staff writers Posted on 16 Dec 2015 |
A recently concluded study confirmed the usefulness of using the protein sTNFR1 (soluble tumor necrosis factor receptor 1) as a biomarker to predict progression of diabetic nephropathy (also referred to as diabetic kidney disease).
Elevations in circulating soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and 2) have been reported in a wide variety of clinical conditions including cancer, congestive heart failure, rheumatoid arthritis, neurological diseases, and infection. In addition, a study conducted at the Joslin Diabetes Center (Boston, MA, USA) has shown that elevated circulating sTNFR1 levels were associated with the subsequent development of advanced diabetic kidney disease in Type I and Type II diabetic patients. These findings were based on TNFR1 data on 1335 patients followed over a four to six year period.
During the study levels of sTNFR1 in serum or plasma were measured with the EKF Diagnostics (Cardiff, United Kingdom) Human sTNFR1 EIA kit. This is a 4.5 hour solid phase quantitative sandwich enzyme immunoassay. The test procedure is based on the sequential addition of sample, polyclonal anti-human sTNFR1 antibody-enzyme conjugate, and colorimetric substrate to microplate wells coated with anti-human sTNFR1 monoclonal antibody. The resultant color intensity is proportional to the concentration of sTNFR1 in the test sample. Test results are determined from a standard curve calibrated against a highly-purified E. coli-expressed recombinant human sTNFR1 protein corresponding to the N-terminal ectodomain.
The Joslin Diabetes Center study was presented at "Kidney Week," the November 3–8, 2015, annual meeting of the American Society for Nephrology held in San Diego (CA, USA).
Related Links:
Joslin Diabetes Center
EKF Diagnostics
Elevations in circulating soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and 2) have been reported in a wide variety of clinical conditions including cancer, congestive heart failure, rheumatoid arthritis, neurological diseases, and infection. In addition, a study conducted at the Joslin Diabetes Center (Boston, MA, USA) has shown that elevated circulating sTNFR1 levels were associated with the subsequent development of advanced diabetic kidney disease in Type I and Type II diabetic patients. These findings were based on TNFR1 data on 1335 patients followed over a four to six year period.
During the study levels of sTNFR1 in serum or plasma were measured with the EKF Diagnostics (Cardiff, United Kingdom) Human sTNFR1 EIA kit. This is a 4.5 hour solid phase quantitative sandwich enzyme immunoassay. The test procedure is based on the sequential addition of sample, polyclonal anti-human sTNFR1 antibody-enzyme conjugate, and colorimetric substrate to microplate wells coated with anti-human sTNFR1 monoclonal antibody. The resultant color intensity is proportional to the concentration of sTNFR1 in the test sample. Test results are determined from a standard curve calibrated against a highly-purified E. coli-expressed recombinant human sTNFR1 protein corresponding to the N-terminal ectodomain.
The Joslin Diabetes Center study was presented at "Kidney Week," the November 3–8, 2015, annual meeting of the American Society for Nephrology held in San Diego (CA, USA).
Related Links:
Joslin Diabetes Center
EKF Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines